Blocking pancreatic cancer by targeting cellular recycling processes
Targeting the autophagy-lysosome system to block pancreatic cancer
This study is looking at how pancreatic cancer cells use a process to recycle their own parts to survive and avoid being attacked by the immune system, and by learning more about this, researchers hope to find new ways to help the immune system better fight the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11041018 on NIH RePORTER |
What this research studies
This research investigates how pancreatic cancer cells use a cellular recycling process called autophagy to survive and grow. The study focuses on the role of the autophagy-lysosome system in degrading specific proteins that help cancer cells evade the immune system. By understanding these mechanisms, the researchers aim to develop strategies to inhibit autophagy, which could enhance the immune response against pancreatic cancer. Patients may benefit from new treatments that improve the effectiveness of their immune system in fighting cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that enhance immune responses against pancreatic cancer, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting autophagy in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Perera, Rushika Miriam — University of California, San Francisco
- Study coordinator: Perera, Rushika Miriam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.